%!PS-Adobe-2.0 
%%BoundingBox: 36 36 577 757 
gsave 
%%Title:       Universal Printer
%%Creator:     SAS Institute Inc. 
%%Version:     9.01.01M3P02022006 
%%Host:        SUN 64 SunOS
%%CreationDate:October 8, 2010
%%Time:        13:35:59.4757
%%LanguageLevel: 1
%%Pages: (atend) 
%%Endcomments 
%%BeginProlog 
/SG{setgray}def /RGB{setrgbcolor}def /HSB{sethsbcolor}def /CMY{setcmykcolor}def /SD{setdash}def /LC{setlinecap}def /LJ{setlinejoin}def /LW{setlinewidth}def /S{show newpath}def /RL {rlineto}def /M{moveto}def /RM {rmoveto}def /NP{stroke newpath}def /SF{selectfont}def /FF{findfont}def /SC{scalefont setfont}def /MK{makefont setfont}def /RF{rectfill}def /RT{rectstroke}def /ARC{arc stroke}def /PF{eofill stroke newpath}def /PIE{arc closepath fill}def /RS{dup stringwidth -1 mul exch -1 mul exch rmoveto show}def/CS{dup stringwidth -0.5 mul exch -0.5 mul exch rmoveto show}def /CLIP {closepath clip newpath }def /gs{gsave}def /gr{grestore}def 
%%ISOLatin1Encoding
/ISOLatin1 {dup findfont dup length dict begin {1 index /FID ne {def} {pop pop} ifelse}forall /Encoding ISOLatin1Encoding def currentdict end definefont pop} def 
%%StandardEncoding
/StdEn {dup findfont dup length dict begin {1 index /FID ne {def} {pop pop} ifelse}forall /Encoding StandardEncoding def currentdict end definefont pop} def 
%%EndProlog 
%%BeginSetup 
%%EndSetup 
%%Page: 1 ? 
36.0 36.0 translate 0.24 LW 1 LC 1 LJ []0 SD 
0 0 0 RGB 0 LC 0 LJ /Courier ISOLatin1 /Courier FF 12.0 SC 1 1 1 RGB 0 0 M 540.0 0 RL 0 720.0 RL -540.0 0 RL 0 -720.0 RL 0 0.24 RL PF 0 0 0 RGB 1 1 1 RGB -36.0 -36.0 M 612.0 0 RL 0 792.0 RL -612.0 0 RL 0 -792.0 RL 0 0.24 RL PF 0 0 0 RGB /Helvetica-BoldOblique ISOLatin1 /Helvetica-BoldOblique FF 9.5 SC 171.6 713.04 M (GLND - Summary of Nosocomial Infections) S 
213.6 702.0 M (By Clinical Site and Type) S 
1 1 1 RGB 0 0 M 540.0 0 RL 0 720.0 RL -540.0 0 RL 0 -720.0 RL 0 0.24 RL PF 0 0 0 RGB 1 1 1 RGB -36.0 -36.0 M 612.0 0 RL 0 792.0 RL -612.0 0 RL 0 -792.0 RL 0 0.24 RL PF 0 0 0 RGB 171.6 713.04 M (GLND - Summary of Nosocomial Infections) S 
213.6 702.0 M (By Clinical Site and Type) S 
-17.52 686.88 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 686.88 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 655.44 M (Site Code) S 
99.36 686.88 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 686.88 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 655.44 M (Type Code) S 
254.88 686.88 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 686.88 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 296.88 676.56 M (A) S 
265.68 666.0 M (Prevalent) S 
308.4 666.0 M (Infec.:) S 
258.96 655.44 M (#) S 
266.88 655.44 M (patients) S 
302.64 655.44 M (\(%) S 
316.8 655.44 M (prev.\)) S 
344.16 686.88 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 686.88 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 403.2 676.56 M (A) S 
375.6 666.0 M (Incident) S 
411.36 666.0 M (Infec.:) S 
348.24 655.44 M (#) S 
356.16 655.44 M (infec.) S 
381.36 655.44 M (\(#patients,) S 
428.16 655.44 M (%) S 
439.2 655.44 M (incid.\)) S 
467.52 686.88 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 686.88 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 509.76 676.56 M (B) S 
478.56 666.0 M (Prevalent) S 
521.28 666.0 M (Infec.:) S 
471.84 655.44 M (#) S 
479.76 655.44 M (patients) S 
515.52 655.44 M (\(%) S 
529.68 655.44 M (prev.\)) S 
-17.52 649.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 649.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -13.68 639.12 M (Bloodstream Infection) S 
99.36 649.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 649.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 639.12 M (Laboratory-confirmed bloodstream) S 
103.2 628.56 M (infection) S 
254.88 649.44 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 649.44 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 639.12 M (3/64 \(4.7%\)) S 
344.16 649.44 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 649.44 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 368.64 639.12 M (18 \(17/64, 26.6%\)) S 
467.52 649.44 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 649.44 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 488.4 639.12 M (5/66 \(7.6%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 612.24 M (Central Nervous System) S 
-13.68 601.68 M (Infection) S 
103.2 612.24 M (Menitigitis or ventriculitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 612.24 M (0/64 \(0.0%\)) S 
376.56 612.24 M (1 \(1/64, 1.6%\)) S 
491.04 612.24 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 585.36 M (Eye, Ear, Nose, Throat,) S 
-13.68 574.8 M (or Mouth Infection) S 
103.2 585.36 M (Oral Cavity \(mouth, tongue, or) S 
103.2 574.8 M (gums\)) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 278.16 585.36 M (0/0 \(0.0%\)) S 
379.2 585.36 M (0 \(0/0, 0.0%\)) S 
488.4 585.36 M (0/66 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 558.48 M (Cardiovascular System) S 
-13.68 547.92 M (Infection) S 
103.2 558.48 M (Mediastinitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 558.48 M (1/64 \(1.6%\)) S 
376.56 558.48 M (0 \(0/64, 0.0%\)) S 
491.04 558.48 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 531.6 M (Eye, Ear, Nose, Throat,) S 
-13.68 521.04 M (or Mouth Infection) S 
103.2 531.6 M (Sinusitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 278.16 531.6 M (0/0 \(0.0%\)) S 
379.2 531.6 M (0 \(0/0, 0.0%\)) S 
488.4 531.6 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 504.72 M (Cardiovascular System) S 
-13.68 494.16 M (Infection) S 
103.2 504.72 M (Arterial or venous infection) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 504.72 M (0/64 \(0.0%\)) S 
376.56 504.72 M (1 \(1/64, 1.6%\)) S 
491.04 504.72 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 477.84 M (Gastrointestinal System) S 
-13.68 467.28 M (Infection) S 
103.2 477.84 M (Gastroenteritis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 477.84 M (1/64 \(1.6%\)) S 
376.56 477.84 M (3 \(3/64, 4.7%\)) S 
488.4 477.84 M (0/66 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 450.96 M (Gastrointestinal System) S 
-13.68 440.4 M (Infection) S 
103.2 450.96 M (Intra-abdominal, not specified) S 
103.2 440.4 M (elsewhere) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 278.16 450.96 M (0/0 \(0.0%\)) S 
379.2 450.96 M (0 \(0/0, 0.0%\)) S 
488.4 450.96 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 424.08 M (Gastrointestinal System) S 
-13.68 413.52 M (Infection) S 
103.2 424.08 M (Gastrointestinal \(GI\) tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 424.08 M (1/64 \(1.6%\)) S 
376.56 424.08 M (1 \(1/64, 1.6%\)) S 
491.04 424.08 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 397.2 M (Pneumonia) S 
103.2 397.2 M (PNU1 - Clinically defined) S 
103.2 386.64 M (pneumonia) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 397.2 M (4/64 \(6.3%\)) S 
376.56 397.2 M (4 \(4/64, 6.3%\)) S 
488.4 397.2 M (5/66 \(7.6%\)) S 
-17.52 353.76 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 353.76 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 370.32 M (Pneumonia) S 
99.36 353.76 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 353.76 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 370.32 M (PNU2 - Pneumonia with specific) S 
103.2 359.76 M (lab findings) S 
254.88 353.76 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 353.76 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 370.32 M (6/64 \(9.4%\)) S 
344.16 353.76 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 353.76 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 376.56 370.32 M (5 \(5/64, 7.8%\)) S 
467.52 353.76 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 353.76 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 488.4 370.32 M (4/66 \(6.1%\)) S 
-17.52 340.8 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 340.8 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 309.36 M (Site Code) S 
99.36 340.8 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 340.8 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 309.36 M (Type Code) S 
254.88 340.8 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 340.8 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 314.16 330.48 M (B) S 
286.56 319.92 M (Incident) S 
322.32 319.92 M (Infec.:) S 
259.2 309.36 M (#) S 
267.12 309.36 M (infec.) S 
292.32 309.36 M (\(#patients,) S 
339.12 309.36 M (%) S 
350.16 309.36 M (incid.\)) S 
-17.52 303.36 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 303.36 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -13.68 293.04 M (Bloodstream Infection) S 
99.36 303.36 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 303.36 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 293.04 M (Laboratory-confirmed bloodstream) S 
103.2 282.48 M (infection) S 
254.88 303.36 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 303.36 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 282.24 293.04 M (11 \(9/66, 13.6%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 266.16 M (Central Nervous System) S 
-13.68 255.6 M (Infection) S 
103.2 266.16 M (Menitigitis or ventriculitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 266.16 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 239.28 M (Eye, Ear, Nose, Throat,) S 
-13.68 228.72 M (or Mouth Infection) S 
103.2 239.28 M (Oral Cavity \(mouth, tongue, or) S 
103.2 228.72 M (gums\)) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 239.28 M (1 \(1/66, 1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 212.4 M (Cardiovascular System) S 
-13.68 201.84 M (Infection) S 
103.2 212.4 M (Mediastinitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 212.4 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 185.52 M (Eye, Ear, Nose, Throat,) S 
-13.68 174.96 M (or Mouth Infection) S 
103.2 185.52 M (Sinusitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 185.52 M (0 \(0/66, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 158.64 M (Cardiovascular System) S 
-13.68 148.08 M (Infection) S 
103.2 158.64 M (Arterial or venous infection) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 158.64 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 131.76 M (Gastrointestinal System) S 
-13.68 121.2 M (Infection) S 
103.2 131.76 M (Gastroenteritis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 131.76 M (1 \(1/66, 1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 104.88 M (Gastrointestinal System) S 
-13.68 94.32 M (Infection) S 
103.2 104.88 M (Intra-abdominal, not specified) S 
103.2 94.32 M (elsewhere) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 104.88 M (0 \(0/66, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 78.0 M (Gastrointestinal System) S 
-13.68 67.44 M (Infection) S 
103.2 78.0 M (Gastrointestinal \(GI\) tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 78.0 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 51.12 M (Pneumonia) S 
103.2 51.12 M (PNU1 - Clinically defined) S 
103.2 40.56 M (pneumonia) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 284.88 51.12 M (7 \(7/66, 10.6%\)) S 
-17.52 7.68 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 7.68 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 24.24 M (Pneumonia) S 
99.36 7.68 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 7.68 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 24.24 M (PNU2 - Pneumonia with specific) S 
103.2 13.68 M (lab findings) S 
254.88 7.68 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 7.68 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 24.24 M (3 \(3/66, 4.5%\)) S 
showpage 
%%Page: 2 ? 
36.0 36.0 translate 0.24 LW 1 LC 1 LJ []0 SD /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 
1 1 1 RGB 0 0 M 540.0 0 RL 0 720.0 RL -540.0 0 RL 0 -720.0 RL 0 0.24 RL PF 0 0 0 RGB 1 1 1 RGB -36.0 -36.0 M 612.0 0 RL 0 792.0 RL -612.0 0 RL 0 -792.0 RL 0 0.24 RL PF 0 0 0 RGB /Helvetica-BoldOblique ISOLatin1 /Helvetica-BoldOblique FF 9.5 SC 171.6 713.04 M (GLND - Summary of Nosocomial Infections) S 
213.6 702.0 M (By Clinical Site and Type) S 
-17.52 686.88 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 686.88 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 655.44 M (Site Code) S 
99.36 686.88 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 686.88 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 655.44 M (Type Code) S 
254.88 686.88 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 686.88 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 296.88 676.56 M (A) S 
265.68 666.0 M (Prevalent) S 
308.4 666.0 M (Infec.:) S 
258.96 655.44 M (#) S 
266.88 655.44 M (patients) S 
302.64 655.44 M (\(%) S 
316.8 655.44 M (prev.\)) S 
344.16 686.88 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 686.88 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 403.2 676.56 M (A) S 
375.6 666.0 M (Incident) S 
411.36 666.0 M (Infec.:) S 
348.24 655.44 M (#) S 
356.16 655.44 M (infec.) S 
381.36 655.44 M (\(#patients,) S 
428.16 655.44 M (%) S 
439.2 655.44 M (incid.\)) S 
467.52 686.88 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 686.88 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 509.76 676.56 M (B) S 
478.56 666.0 M (Prevalent) S 
521.28 666.0 M (Infec.:) S 
471.84 655.44 M (#) S 
479.76 655.44 M (patients) S 
515.52 655.44 M (\(%) S 
529.68 655.44 M (prev.\)) S 
-17.52 649.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 649.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -13.68 639.12 M (Reproductive Tract) S 
-13.68 628.56 M (Infection) S 
99.36 649.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 649.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 639.12 M (Other infections of the male or) S 
103.2 628.56 M (female reproductive tract) S 
254.88 649.44 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 649.44 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 278.16 639.12 M (0/0 \(0.0%\)) S 
344.16 649.44 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 649.44 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 379.2 639.12 M (0 \(0/0, 0.0%\)) S 
467.52 649.44 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 649.44 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 488.4 639.12 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 612.24 M (Surgical Site Infection) S 
103.2 612.24 M (Deep incisional primary SSI) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 612.24 M (1/64 \(1.6%\)) S 
376.56 612.24 M (0 \(0/64, 0.0%\)) S 
491.04 612.24 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 595.92 M (Surgical Site Infection) S 
103.2 595.92 M (Intra-abdominal, not specified) S 
103.2 585.36 M (elsewhere) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 595.92 M (1/64 \(1.6%\)) S 
376.56 595.92 M (4 \(3/64, 4.7%\)) S 
488.4 595.92 M (4/66 \(6.1%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 569.04 M (Surgical Site Infection) S 
103.2 569.04 M (Gastrointestinal \(GI\) tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 569.04 M (1/64 \(1.6%\)) S 
376.56 569.04 M (0 \(0/64, 0.0%\)) S 
491.04 569.04 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 552.72 M (Surgical Site Infection) S 
103.2 552.72 M (Superficial incisional primary SSI) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 278.16 552.72 M (0/0 \(0.0%\)) S 
379.2 552.72 M (0 \(0/0, 0.0%\)) S 
488.4 552.72 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 536.4 M (Surgical Site Infection) S 
103.2 536.4 M (Skin) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 536.4 M (1/64 \(1.6%\)) S 
376.56 536.4 M (0 \(0/64, 0.0%\)) S 
488.4 536.4 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 520.08 M (Skin and Soft Tissue) S 
-13.68 509.52 M (Infection) S 
103.2 520.08 M (Soft tissue) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 278.16 520.08 M (0/0 \(0.0%\)) S 
379.2 520.08 M (0 \(0/0, 0.0%\)) S 
488.4 520.08 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 493.2 M (Surgical Site Infection) S 
103.2 493.2 M (Soft tissue) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 493.2 M (0/64 \(0.0%\)) S 
376.56 493.2 M (1 \(1/64, 1.6%\)) S 
491.04 493.2 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 476.88 M (Urinary Tract Infection) S 
103.2 476.88 M (Asymptomatic bacteriuria) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 476.88 M (3/64 \(4.7%\)) S 
373.92 476.88 M (9 \(8/64, 12.5%\)) S 
488.4 476.88 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 460.56 M (Surgical Site Infection) S 
103.2 460.56 M (Unknown) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 460.56 M (0/64 \(0.0%\)) S 
376.56 460.56 M (1 \(1/64, 1.6%\)) S 
491.04 460.56 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 444.24 M (Urinary Tract Infection) S 
103.2 444.24 M (Symptomatic urinary tract infection) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 444.24 M (0/64 \(0.0%\)) S 
368.64 444.24 M (10 \(10/64, 15.6%\)) S 
488.4 444.24 M (1/66 \(1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 427.92 M (Skin and Soft Tissue) S 
-13.68 417.36 M (Infection) S 
103.2 427.92 M (Breast abscess or mastitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 427.92 M (0/64 \(0.0%\)) S 
376.56 427.92 M (1 \(1/64, 1.6%\)) S 
491.04 427.92 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 401.04 M (Urinary Tract Infection) S 
103.2 401.04 M (Other infections of the urinary tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 401.04 M (0/64 \(0.0%\)) S 
376.56 401.04 M (1 \(1/64, 1.6%\)) S 
491.04 401.04 M (0/0 \(0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 384.72 M (Overall) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 270.24 384.72 M (19/64 \(29.7%\)) S 
368.64 384.72 M (60 \(32/64, 50.0%\)) S 
483.12 384.72 M (21/66 \(31.8%\)) S 
-17.52 362.4 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 362.4 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 362.4 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 362.4 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 362.4 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 362.4 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 362.4 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 362.4 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 362.4 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 362.4 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 349.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 349.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 318.0 M (Site Code) S 
99.36 349.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 349.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 318.0 M (Type Code) S 
254.88 349.44 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 349.44 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 314.16 339.12 M (B) S 
286.56 328.56 M (Incident) S 
322.32 328.56 M (Infec.:) S 
259.2 318.0 M (#) S 
267.12 318.0 M (infec.) S 
292.32 318.0 M (\(#patients,) S 
339.12 318.0 M (%) S 
350.16 318.0 M (incid.\)) S 
-13.68 301.68 M (Reproductive Tract) S 
-13.68 291.12 M (Infection) S 
103.2 301.68 M (Other infections of the male or) S 
103.2 291.12 M (female reproductive tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 301.68 M (0 \(0/66, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 274.8 M (Surgical Site Infection) S 
103.2 274.8 M (Deep incisional primary SSI) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 274.8 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 258.48 M (Surgical Site Infection) S 
103.2 258.48 M (Intra-abdominal, not specified) S 
103.2 247.92 M (elsewhere) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 258.48 M (2 \(2/66, 3.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 231.6 M (Surgical Site Infection) S 
103.2 231.6 M (Gastrointestinal \(GI\) tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 231.6 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 215.28 M (Surgical Site Infection) S 
103.2 215.28 M (Superficial incisional primary SSI) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 215.28 M (1 \(1/66, 1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 198.96 M (Surgical Site Infection) S 
103.2 198.96 M (Skin) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 198.96 M (0 \(0/66, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 182.64 M (Skin and Soft Tissue) S 
-13.68 172.08 M (Infection) S 
103.2 182.64 M (Soft tissue) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 182.64 M (1 \(1/66, 1.5%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 155.76 M (Surgical Site Infection) S 
103.2 155.76 M (Soft tissue) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 155.76 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 139.44 M (Urinary Tract Infection) S 
103.2 139.44 M (Asymptomatic bacteriuria) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 139.44 M (5 \(5/66, 7.6%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 123.12 M (Surgical Site Infection) S 
103.2 123.12 M (Unknown) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 123.12 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 106.8 M (Urinary Tract Infection) S 
103.2 106.8 M (Symptomatic urinary tract infection) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 106.8 M (7 \(6/66, 9.1%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 90.48 M (Skin and Soft Tissue) S 
-13.68 79.92 M (Infection) S 
103.2 90.48 M (Breast abscess or mastitis) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 90.48 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 63.6 M (Urinary Tract Infection) S 
103.2 63.6 M (Other infections of the urinary tract) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 63.6 M (0 \(0/0, 0.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 47.28 M (Overall) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 279.6 47.28 M (39 \(22/66, 33.3%\)) S 
-17.52 24.96 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 24.96 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 24.96 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 24.96 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 24.96 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 24.96 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF showpage 
%%Page: 3 ? 
36.0 36.0 translate 0.24 LW 1 LC 1 LJ []0 SD /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 
1 1 1 RGB 0 0 M 540.0 0 RL 0 720.0 RL -540.0 0 RL 0 -720.0 RL 0 0.24 RL PF 0 0 0 RGB 1 1 1 RGB -36.0 -36.0 M 612.0 0 RL 0 792.0 RL -612.0 0 RL 0 -792.0 RL 0 0.24 RL PF 0 0 0 RGB /Helvetica-BoldOblique ISOLatin1 /Helvetica-BoldOblique FF 9.5 SC 171.6 713.04 M (GLND - Summary of Nosocomial Infections) S 
213.6 702.0 M (By Clinical Site and Type) S 
-17.52 686.88 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 686.88 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 655.44 M (Site Code) S 
99.36 686.88 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 686.88 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 655.44 M (Type Code) S 
254.88 686.88 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 686.88 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 296.88 676.56 M (A) S 
265.68 666.0 M (Prevalent) S 
308.4 666.0 M (Infec.:) S 
258.96 655.44 M (#) S 
266.88 655.44 M (patients) S 
302.64 655.44 M (\(%) S 
316.8 655.44 M (prev.\)) S 
344.16 686.88 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 686.88 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 403.2 676.56 M (A) S 
375.6 666.0 M (Incident) S 
411.36 666.0 M (Infec.:) S 
348.24 655.44 M (#) S 
356.16 655.44 M (infec.) S 
381.36 655.44 M (\(#patients,) S 
428.16 655.44 M (%) S 
439.2 655.44 M (incid.\)) S 
467.52 686.88 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 686.88 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 509.76 676.56 M (B) S 
478.56 666.0 M (Prevalent) S 
521.28 666.0 M (Infec.:) S 
471.84 655.44 M (#) S 
479.76 655.44 M (patients) S 
515.52 655.44 M (\(%) S 
529.68 655.44 M (prev.\)) S 
-17.52 649.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 649.44 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -13.68 639.12 M (Totals by site:) S 
99.36 649.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 649.44 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 649.44 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 649.44 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 649.44 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 649.44 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 649.44 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 649.44 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF -13.68 622.8 M (Emory) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 272.88 622.8 M (5/26 \(19.2%\)) S 
368.64 622.8 M (27 \(14/26, 53.8%\)) S 
485.76 622.8 M (6/25 \(24.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 606.48 M (Miriam) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 606.48 M (3/4 \(75.0%\)) S 
376.56 606.48 M (6 \(3/4, 75.0%\)) S 
488.4 606.48 M (2/5 \(40.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 590.16 M (Vanderbilt) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 272.88 590.16 M (4/16 \(25.0%\)) S 
373.92 590.16 M (5 \(3/16, 18.8%\)) S 
485.76 590.16 M (5/18 \(27.8%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 573.84 M (Colorado) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 272.88 573.84 M (6/16 \(37.5%\)) S 
368.64 573.84 M (21 \(11/16, 68.8%\)) S 
485.76 573.84 M (7/16 \(43.8%\)) S 
-17.52 551.52 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 551.52 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 557.52 M (Wisconsin) S 
99.36 551.52 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 551.52 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 551.52 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 551.52 M 89.28 0 RL 0 0.48 RL -89.28 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 275.52 557.52 M (1/2 \(50.0%\)) S 
344.16 551.52 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 344.16 551.52 M 123.36 0 RL 0 0.48 RL -123.36 0 RL 0 -0.48 RL 0 0.24 RL PF 376.56 557.52 M (1 \(1/2, 50.0%\)) S 
467.52 551.52 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 467.52 551.52 M 89.76 0 RL 0 0.48 RL -89.76 0 RL 0 -0.48 RL 0 0.24 RL PF 491.04 557.52 M (0/2 \(0.0%\)) S 
-17.52 538.56 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 538.56 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 507.12 M (Site Code) S 
99.36 538.56 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 538.56 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 103.2 507.12 M (Type Code) S 
254.88 538.56 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 538.56 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 314.16 528.24 M (B) S 
286.56 517.68 M (Incident) S 
322.32 517.68 M (Infec.:) S 
259.2 507.12 M (#) S 
267.12 507.12 M (infec.) S 
292.32 507.12 M (\(#patients,) S 
339.12 507.12 M (%) S 
350.16 507.12 M (incid.\)) S 
-13.68 490.8 M (Totals by site:) S 
-13.68 474.48 M (Emory) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 282.24 474.48 M (10 \(6/25, 24.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 458.16 M (Miriam) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 287.52 458.16 M (7 \(3/5, 60.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 441.84 M (Vanderbilt) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 282.24 441.84 M (13 \(9/18, 50.0%\)) S 
/Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 425.52 M (Colorado) S 
/Helvetica ISOLatin1 /Helvetica FF 9.5 SC 284.88 425.52 M (9 \(4/16, 25.0%\)) S 
-17.52 403.2 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF -17.52 403.2 M 116.88 0 RL 0 0.48 RL -116.88 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica-Oblique ISOLatin1 /Helvetica-Oblique FF 9.5 SC -13.68 409.2 M (Wisconsin) S 
99.36 403.2 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 99.36 403.2 M 155.52 0 RL 0 0.48 RL -155.52 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 403.2 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF 254.88 403.2 M 123.84 0 RL 0 0.48 RL -123.84 0 RL 0 -0.48 RL 0 0.24 RL PF /Helvetica ISOLatin1 /Helvetica FF 9.5 SC 290.16 409.2 M (0 \(0/2, 0.0%\)) S 
showpage 
grestore 
%%Pages: 3
%%End of Document 
%%EOF 
